BioLineRx Ltd. - American Depositary Shares (BLRX) earnings
BLRX earnings moved a median of +2.08% by the close. Quarterly and annual BLRX reports and results, each read against the price at its own news timestamp. Back to the BLRX overview →
20 measured BLRX earnings events.
Where these BLRX earnings landedvs 20 measured BLRX earnings reactions
| Middle 50% of BLRX earnings reactions | -2.57% to +3.01% |
|---|---|
| Median reaction (to close) | +2.08% |
| Measured reactions | 20 |
Point-in-time · zero look-ahead
Half of the 20 BLRX earnings events with a measured close landed between -2.57% and +3.01%; 60% closed up.
| Date | Headline | Event | 5-min | To close |
|---|---|---|---|---|
| BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | -10.35% | -3.45% | |
| BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 | Press release | — | -2.40% | |
| BioLineRx Reports First Quarter 2026 Financial Results and Provides Corporate Update | Press release | -5.46% | +2.12% | |
| BioLineRx to Report First Quarter 2026 Results on May 27, 2026 | Press release | — | +4.96% | |
| BioLineRx to Report 2025 Annual Results on March 23, 2026 | Press release | +0.00% | +2.73% | |
| BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update | Press release | -1.75% | +2.04% | |
| BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 | Press release | +0.00% | -4.46% | |
| BioLineRx Reports Second Quarter 2025 Financial Results and Provides Corporate Update | Press release | -3.08% | -2.08% | |
| BioLineRx to Report Second Quarter 2025 Results on August 14, 2025 | Press release | +0.00% | -6.41% | |
| BioLineRx Reports First Quarter 2025 Financial Results and Provides Corporate Update | Press release | -0.55% | +1.66% | |
| BioLineRx to Report First Quarter 2025 Results on May 27, 2025 | Press release | -2.14% | +11.31% | |
| BioLineRx to Report 2024 Annual Results on March 31, 2025 | Press release | -1.73% | -1.16% | |
| BioLineRx Reports Third Quarter 2024 Financial Results and Provides Update on Transformation to Drive Shareholder Value | Press release | -5.14% | -3.10% | |
| BioLineRx to Report Third Quarter 2024 Results on November 25, 2024 | Press release | +1.85% | +2.83% | |
| BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates | Press release | -1.43% | -3.10% | |
| BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 | Press release | -2.31% | +4.15% | |
| BioLineRx Reports First Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates | Press release | +2.19% | +3.48% | |
| BioLineRx to Report First Quarter 2024 Results on May 28, 2024 | Press release | +0.00% | +2.85% | |
| BioLineRx Reports Third Quarter 2023 Financial Results and Recent Corporate and Portfolio Updates | Press release | -0.61% | +4.29% | |
| BioLineRx to Report Third Quarter 2023 Results on November 20, 2023 | Press release | +2.17% | +2.17% |
Keep exploring
More BLRX: analyst actions → · SEC filings → · BLRX overview →
Other Healthcare names and their earnings
| Ticker | Events | Median 30-min | % positive |
|---|---|---|---|
| Fresenius Medical Care AG American Depositary Shares (Each representing 1/2 of an Ordinary Share) (FMS) | 150 | -0.01% | 48% |
| Sol-Gel Technologies Ltd. - Ordinary Shares (SLGL) | 149 | 0.00% | 42% |
| INMED PHARMACEUTICALS (IMLFF) | 148 | 0.00% | 48% |
| Akari Therapeutics Plc - American Depositary Shares (AKTX) | 146 | 0.00% | 45% |
Same sector, same measurement: percent move vs. the price at the news timestamp, read at 30 minutes. Sample sizes differ, so the medians are comparable but the confidence behind them is not. These are each name’s all-news baseline, not its earnings — that is what the link opens.